NORTHERN NEVADA SIERRA MEDICAL CNTR
1. Target Overview & Investment Thesis
NORTHERN NEVADA SIERRA MEDICAL CNTR is a 158-bed under-performing / distressed in WASHOE, NV with $61.7M in net patient revenue and a -70.3% operating margin. The hospital serves a payer mix of 21.5% Medicare, 6.1% Medicaid, and 72.4% commercial.
Thesis: Undervalued. Our ML models identify $4.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -70.3% to -63.0% (+736bps).
| Net Revenue HCRIS | $61.7M |
| Current EBITDA COMPUTED | $-43.4M |
| Operating Margin COMPUTED | -70.3% |
| Occupancy HCRIS | 34.0% |
| Revenue / Bed COMPUTED | $391K |
| Net-to-Gross HCRIS | 10.7% |
| Distress Probability ML | 51.3% |
2. Market Context & Competitive Position
NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of -70.3% places it below the state median. Among 20 size-comparable peers (79-316 beds), the median margin is 0.4%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (79-316), prioritizing same-state peers. 20 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| NORTHERN NEVADA SIERRA MEDICAL (Target) | NV | 158 | $61.7M | -70.3% |
| SPRING VALLEY HOSPITAL MEDICAL | NV | 301 | $397.8M | 8.4% |
| CARSON TAHOE REGIONAL HEALTHCA | NV | 175 | $365.4M | 3.0% |
| HENDERSON HOSPITAL | NV | 288 | $358.3M | 21.5% |
| SOUTHERN HILLS HOSPITAL & MEDI | NV | 205 | $317.7M | 11.7% |
| VALLEY HOSPITAL MEDICAL CENTER | NV | 297 | $315.7M | 2.9% |
| DESERT SPRINGS HOSPITAL MEDICA | NV | 190 | $182.8M | -39.4% |
| ST. ROSE DOMINICAN - SAN MARTI | NV | 130 | $179.5M | -18.6% |
| NORTHERN NEVADA MEDICAL CENTER | NV | 88 | $150.8M | 10.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.3M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.2M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.2M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $751K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $40K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-43.4M |
| + RCM Uplift | +$4.5M |
| Pro Forma EBITDA | $-38.9M |
| Current Margin | -70.3% |
| Pro Forma Margin | -63.0% |
| WC Released (1x) | $2.4M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-66.8M | $-241.1M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-66.8M | $-286.9M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-60.1M | $-293.6M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-60.1M | $-338.0M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-73.5M | $-242.1M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-73.5M | $-290.2M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Low occupancy | At 34.0%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 51.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 20 hospitals with 79-316 beds
- Same-state prioritization (n=21)
- Comp margins: P25=-13.0% / P50=0.4% / P75=8.7%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.